DOCSLIB.ORG

Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Published OnlineFirst July 1, 2016; DOI: 10.1158/1535-7163.MCT-16-0008 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy Le Li1, Hua Chen1, Yue Gao2, Yong-Wei Wang1, Guang-Quan Zhang1, Shang-Ha Pan1, Liang Ji1, Rui Kong1, Gang Wang1, Yue-Hui Jia3, Xue-Wei Bai1, and Bei Sun1 Abstract Recently, pancreatic ductal adenocarcinoma (PDAC) has LC3, P62, and LAMP-2. Mechanistically, we found that MALAT1 emerged as one of the most aggressive malignant tumors with interacted with RNA binding protein HuR, and silencing of the worst prognosis. Previous studies have demonstrated that MALAT1 greatly enhanced the posttranscriptional regulation long noncoding RNA metastasis-associated lung adenocarcinoma of TIA-1 and had further effects on inhibiting autophagy. transcript 1 (MALAT1) is increased in pancreatic cancer and is MALAT1 was speculated to regulate tumorigenesis via HuR- identified as a diagnostic biomarker. Nonetheless, the molecular TIA-1–mediated autophagic activation. Hence, we investigated mechanism of elevated MALAT1 levels and tumor aggressiveness the biological properties of MALAT1 in terms of tumor prolif- remains unknown. In this study, MALAT1 was found to be highly eration and metastasis by promoting autophagy in vitro. In expressed in PDAC tissues, and elevated expression was associated brief, these data demonstrate that MALAT1 could facilitate with poorer prognoses. In addition, MALAT1 was positively the advanced progression of tumors in vivo. Our study high- linearly correlated with the expression of LC3B mRNA. Further- lights the new roles of MALAT1 on protumorigenic functioning more, several molecules involved in cellular autophagic flux were and anticancer therapy via activating autophagy in pancreatic modulated following the downregulation of MALAT1, including cancer. Mol Cancer Ther; 15(9); 2232–43. Ó2016 AACR. Introduction 1 (MALAT1), also known as noncoding nuclear-enriched abun- dant transcript 2 (NEAT2), is highly conserved among mammals Pancreatic ductal adenocarcinoma (PDAC) is one of the most and is strongly expressed in the nucleus. MALAT1 was first aggressive malignancies. The overall 5-year survival of PDAC identified as a sign of metastasis in lung cancer (7). Similarly, ranges from 3% to 5%, even with curative tumor resection and early reports demonstrated that MALAT1 was highly expressed in chemotherapy (1). The grave prognosis associated with PDAC is pancreatic cancer hepatocellular carcinoma, prostate cancer, and primarily due to delayed diagnoses and a lack of effective treat- other malignancies (8–10). Few studies have confirmed the strong ment, which emphasizes the importance of identifying PDAC in association between MALAT1 and poor pancreatic cancer prog- earlier stages and establishing better therapeutic targets (2). noses (11). However, the molecular mechanism for its cancer- Long noncoding RNA (lncRNA) is a class of ncRNA with a promoting effect is yet to be defined. length of more than 200 NTs. So far, a large number of lncRNAs Autophagy is an evolutionarily conserved catabolic process and have been recognized by high-throughput transcriptome analysis mechanism for the degradation of cellular proteins, which is (HTTA). They play important regulatory roles in the expression of functional in cell growth regulation and intracellular homeostasis nearby genes, the activation and localization of proteins, and the (12, 13). Autophagy seems complicated and has both protumori- organization of small RNAs (3). LncRNAs are also critical regu- genic and tumor-suppressive roles in pancreatic cancer. It has also lators in tumor-related apoptosis, autophagy, and tumor metas- been described as a moderator of cellular invasion and metastasis tasis (4–6). Metastasis-associated lung adenocarcinoma transcript by impacting cell biological phenotypes (14–16). Increasing evidence suggests that lncRNAs regulate the process of autophagy by means of interacting with RNA-binding proteins (RBP), as well 1Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. as by suppressing the induction of miRNAs (17). However, the 2Department of General Surgery, Cleveland Clinic Foundation, Cleve- existence of this regulatory effect in pancreatic cancer is still under land, Ohio. 3Department of Epidemiology and Biostatistics, School of investigation. Public Health, Qiqihar Medical University, Qiqihar, Heilongjiang, China. In this study, we correlated the clinical significance of MALAT1 Note: Supplementary data for this article are available at Molecular Cancer expression with the level of autophagy in PDAC samples. Then, we Therapeutics Online (http://mct.aacrjournals.org/). explored the roles of MALAT1 in tumor progression and found Corresponding Author: Bei Sun, Department of Pancreatic and Biliary Surgery, that MALAT1 upregulated cellular autophagy in pancreatic cancer The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, cell lines. Furthermore, our study also demonstrated that MALAT1 Nangang District, Harbin 150001, Heilongjiang Province, China. Phone: 8645- directly interacts with HuR and alters the biological process of 1855-55721; Fax: 8645-1536-43849; E-mail: [email protected] autophagy via enhancing the regulation of TIA-1 posttranscrip- doi: 10.1158/1535-7163.MCT-16-0008 tionally. Our study eventually suggested that MALAT1 may accel- Ó2016 American Association for Cancer Research. erate the proliferation and metastasis of cancer cells through the 2232 Mol Cancer Ther; 15(9) September 2016 Downloaded from mct.aacrjournals.org on October 2, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst July 1, 2016; DOI: 10.1158/1535-7163.MCT-16-0008 MALAT1 Promotes Cancer Proliferation and Metastasis stimulation of autophagy. MALAT1 functioned as a protumori- The yellow dots that result from merging the red and green genic oncogene in pancreatic cancer in vitro and in vivo. channels indicate autophagosomes, while the red dots that not overlay with green dots are indicative of autolysosomes. The Materials and Methods number of GFP and mRFP dots was determined by manual counting of the fluorescent puncta in five high-power fields Cell culture (40Â, Olympus). Bxpc-3 and Panc-1 and human pancreatic duct epithelial (HPDE) cells were purchased from the ATCC from 2010. All cell lines were authenticated by short tandem repeat (STR) and RNA pull-down assay genotyped upon re-expansions and tested within 6 months of The full-length MALAT1 fragment cleaved by the EcoRI enzyme authentication. Aspc-1, CFPAC, and SW1990 were purchased was excised from the vector pCRII-TOPO. RNA transcript probes from the Type Culture Collection of the Chinese Academy of were synthesized using a MEGAscript T7 kit (Ambion), following Sciences (Shanghai, China) and used within 6 months after the the protocol provided by the manufacturer. A biotinylated RNA cells were ordered. Aspc-1, Bxpc-3, and Panc-1 were cultured in probe synthesized in a 20 mL MEGAscript transcription reaction by RPMI1640 medium (Hyclone), and CFPAC, SW1990, and HPDE adding 1.25 mL 20 mmol/L biotinylated UTP, Biotin-16-UTP were cultured in DMEM (Gibco), all supplemented with 10% FBS (Roche). The synthesized RNA probes were purified using an (Gibco), 1% penicillin, and streptomycin at 37 C with 5% CO2. RNeasy Protect Mini kit (Qiagen). Whole cells were grown to 90% confluence and washed three times with PBS. Then, the cells Patients and specimens were resuspended in CHAPS buffer (10 mmol/L Tris-HCl pH 7.4, This study was approved by the Ethics Committee of the First 1 mmol/L MgCl2, 1 mmol/L EGTA, 0.5% CHAPS, 10% glycerol, Affiliated Hospital of Harbin Medical University. The 52 PDAC 0.1 mmol/L PMSF, 5 mmol/L 2-ME) and incubated 30 minutes specimens used in this experiment were obtained from patients on ice for lysing. The cell lysates were obtained by centrifugation at  who underwent pancreaticoduodenectomy for pancreatic head 10,000 g for 10 minutes at 4 C. The supernatants were collected cancer in the Department of Pancreatic and Biliary Surgery (The and the protein concentration was determined using the Bio-Rad m First Affiliated Hospital of Harbin Medical University, Harbin, protein assay (Bio-Rad). The reaction mixture contained 200 gof m 0 Heilongjiang, China) from January 2008 to January 2010. All cell extracts and 3 g of biotinylated MALAT1 5 -UTR RNA probe. fi m patients underwent standard resection without receiving chemo- The reaction mixture's nal volume was adjusted to 100 L with therapy or radiotherapy preoperatively or postoperatively. The RNA mobility shift buffer (5 mmol/L HEPES, 40 mmol/L KCl, patients' detailed clinicopathologic characteristics are listed in 0.1 mmol/L EDTA, 2 mmol/L MgCl2, 2 mmol/L dithiothreitol, Supplementary Table S1. 1 U RNasin and 0.25 mg/mL heparin). The mixture was incubated for 15 minutes at 30C, and then added to 400 mL of Streptavidin MagneSphere Paramagnetic Particles (Promega) for binding at RNA isolation, reverse transcription, and quantitative real-time room temperature for 10 minutes. Then, the RNA–protein com- PCRqRT-PCR plexes were washed seven times with the RNA mobility shift buffer RNA isolation and the PCR amplification conditions were without heparin. After washing, 30 mLof2ÂSDS-PAGE sample followed as previously described (18). Quantitative real-time buffer was added to the reaction mixture. The retrieved proteins (qRT-PCR; SYBR Green Assay, Roche Diagnostics GmbH) was were detected using standard Western blot analysis. performed on Applied Biosystems 7500 Real-Time PCR System. The relative expression levels of mRNAs were calculated and ÀDD quantified using the 2 CT method after normalization for the RNA-binding immunoprecipitation expression of the control, and GAPDH served as the endogenous The cells (1 107) were lysed with 500 mL of lysis buffer (10 control. The primer sequences were designed by Primer 5.0 and mmol/L Tris-HCl pH 7.4, 1 mmol/L MgCl2, 1 mmol/L EGTA, purchased from Invitrogen. 0.5% CHAPS, 10% glycerol, 0.1 mmol/L PMSF, 5 mmol/L 2-ME) for 20 minutes on ice.
Load more

Recommended publications
  • Role of MALAT1 in Gynecological Cancers: Pathologic and Therapeutic Aspects (Review)
    ONCOLOGY LETTERS 21: 333, 2021 Role of MALAT1 in gynecological cancers: Pathologic and therapeutic aspects (Review) FENG‑HUA QIAO1, MIN TU2 and HONG‑YAN LIU3 Departments of 1Gynecology and 2Orthopedics, Second People's Hospital of Jingmen; 3Department of Gynecology, Maternal and Child Health Hospital of Jingmen, Jingmen, Hubei 448000, P.R. China Received June 28, 2020; Accepted February 2, 2021 DOI: 10.3892/ol.2021.12594 Abstract. Gynecological cancers, including breast, ovarian, 5. Targeting MALAT1 in gynecological cancer therapeutics uterine, vaginal, cervical and vulvar cancers are among the 6. Future research major threats to modern life, particularly to female health. 7. Conclusions Long non‑coding RNAs (lncRNAs) play critical roles in normal development of organisms, as well as the tumorigenesis process, and metastasis‑associated lung adenocarcinoma tran‑ 1. Introduction script 1 (MALAT1) is a large infrequently spliced lncRNA, which have been implicated in different gynecological cancers. Gynecologic cancer is any cancer of the female reproduc‑ MALAT1 is overexpressed in breast, ovarian, cervical and tive organs, including ovarian, uterine, vaginal, cervical and endometrial cancers, which initiates cancer progression by vulvar cancers. Generally, all women are at risk of devel‑ inducing changes in the expression of several anti‑apoptotic oping gynecological cancers, and risk increases with age (1). and epithelial‑to‑mesenchymal transition‑related genes. Each gynecologic cancer is unique, with different signs and Targeting MALAT1 is an important strategy to combat symptoms, different risk factors and different therapeutic strat‑ gynecological cancers, and application of RNA‑interference egies (2,3). Gynecological cancers are associated with high technology and chemotherapeutic process are crucial to target mortality rates worldwide as it is difficult to detect the cancers and minimize MALAT1 activity.
    [Show full text]
  • Long Non-Coding RNA MALAT1 Drives Gastric Cancer Progression By
    Li et al. Cancer Cell Int (2017) 17:44 DOI 10.1186/s12935-017-0408-8 Cancer Cell International PRIMARY RESEARCH Open Access Long non‑coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR‑1297 Jijun Li, Jinghua Gao*, Wen Tian, Yongsheng Li and Jinghua Zhang Abstract Background: Emerging evidences have verified that long non-coding RNAs (lncRNAs) play important regulatory roles in the pathogenesis and progression of cancers. lncRNAs metastasis associated lung adenocarcinoma transcript 1 (MALAT1) have been found to be up-regulated in some human cancers. The main objective of this study was to investigate the expression level and biological function of MALAT1 in gastric cancer (GC). Methods: Quantificational real-time polymerase chain reaction (qRT-PCR) was performed to detect the mRNA levels of MALAT1 in 78 paired gastric carcinoma tissues and adjacent normal tissues, and the associations of MALAT1 expres- sion with the clinicopathological features were analyzed, and the prognosis of gastric carcinoma patients was evalu- ated. The HMGB2 mRNA and protein expressions were detected by qRT-PCR and western-blot analysis. Luciferase reporter assay was used to determine miR-1297 was a target of MALAT1. Results: In this study, we demonstrated MALAT1 was up-regulation in GC tissues compared with adjacent normal tissues and higher MALAT1 expression was correlated with local invasion, lymph node metastasis and TNM stage. Patients with higher MALAT1 expression predicted a shorter survival and poor prognosis. Functionally, we revealed that MALAT1 promoted cells proliferation and invasion in GC. Mechanistically, our results demonstrated that MALAT1 was negatively correlation with miR-1297 and functioned as a molecular sponging miR-1297, antagonizing its ability to suppress HMGB2 expression.
    [Show full text]
  • University of Florida Thesis Or Dissertation Formatting
    GENES AND GENOMES OF REPTILES By JENA LIND CHOJNOWSKI A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2010 1 © 2010 Jena Lind Chojnowski 2 To my mother and father and to all those who have overcome their own setbacks, big or small, to succeed in their happiness 3 ACKNOWLEDGMENTS I would like to thank my emotional support system, which includes my mother (my best cheerleader), my friends who had to deal with my venting, and my soccer friends who helped with my frustrations. My undergraduate assistants, especially Vipa Bernhardt, Jenessa Graham, and Rachel Seibert, were crucial in the beginning stages of my work. I would also like to thank my committee members: Mike Miyamoto, Lou Guillette, Jr., Mike Fields, Rebecca Kimball, and my advisor Ed Braun. I would like to thank Mike Miyamoto for always being positive, Lou Guillette for his invaluable technical help and pushing me to the next level, and Mike Fields for showing me there is life outside of the lab. I would like to give special thanks to Rebecca Kimball for helping me every step of the way by not only providing emotional support but also technical and psychological support. Without her expertise I would not be where I am today. Ed Braun, my advisor, is my teacher, my mentor, and my friend, all things necessary for a successful and fruitful pairing, which constitutes our union. 4 TABLE OF CONTENTS page ACKNOWLEDGMENTS .................................................................................................. 4 LIST OF TABLES ...........................................................................................................
    [Show full text]
  • MALAT1 Is Associated with Poor Response to Oxaliplatin-Based
    Published OnlineFirst January 9, 2017; DOI: 10.1158/1535-7163.MCT-16-0591 Companion Diagnostics and Cancer Biomarkers Molecular Cancer Therapeutics MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 Peilong Li1, Xin Zhang1, Haiyan Wang2, Lili Wang1, Tong Liu1, Lutao Du1, Yongmei Yang1, and Chuanxin Wang3 Abstract A major reason for oxaliplatin chemoresistance in colorectal E-cadherin expression and inhibits oxaliplatin-induced EMT in cancer is the acquisition of epithelial–mesenchymal transition colorectal cancer cells. EZH2 is highly expressed and associated (EMT) in cancer cells. The long noncoding RNA (lncRNA), with the 30 end region of lncRNA MALAT1 in colorectal cancer, MALAT1, is a highly conserved nuclear ncRNA and a key regulator and this association suppressed the expression of E-cadherin. of metastasis development in several cancers. However, its role in Furthermore, targeted inhibition of MALAT1 or EZH2 reversed oxaliplatin-induced metastasis and chemoresistance is not well EMT and chemoresistance induced by oxaliplatin. Finally, the known. In this study, we aim to investigate the prognostic and interaction between lncRNA MALAT1 and miR-218 was observed, therapeutic role of lncRNA MALAT1 in colorectal cancer patients which further indicated its prognostic value in patients who receiving oxaliplatin-based therapy and further explore the poten- received standard FOLFOX (oxaliplatin combine with 5-fluoro- tial transcriptional regulation through interaction with EZH2 uracil and leucovorin) treatment. In conclusion, this study illu- based on the established HT29 oxaliplatin-resistant cells. Our minates the prognostic role of lncRNA MALAT1 in colorectal results showed that high MALAT1 expression was associated cancer patients receiving oxaliplatin-based treatment and further with reduced patient survival and poor response to oxaliplatin- demonstrates how lncRNA MALAT1 confers a chemoresistant based chemotherapy in advanced colorectal cancer patients.
    [Show full text]
  • End Processing and Maturation of MALAT1 Lncrna Xinying Zong1, Shinichi Nakagawa2, Susan M
    Nucleic Acids Research Advance Access published January 29, 2016 Nucleic Acids Research, 2016 1 doi: 10.1093/nar/gkw047 Natural antisense RNA promotes 3 end processing and maturation of MALAT1 lncRNA Xinying Zong1, Shinichi Nakagawa2, Susan M. Freier3, Jingyi Fei4, Taekjip Ha4, Supriya G. Prasanth1 and Kannanganattu V. Prasanth1,* 1Department of Cell and Developmental Biology, University of Illinois Urbana, IL 61801, USA, 2RNA Biology Laboratory, RIKEN Advanced Research Institute, Wako, Saitama 351-0198, Japan, 3Ionis Pharmaceuticals, Carlsbad, CA, USA and 4Center for Physics of living cells, Department of Physics, University of Illinois, Urbana, IL, USA Received July 09, 2015; Revised December 30, 2015; Accepted January 17, 2016 ABSTRACT is critical for the termination of RNA Pol II and also deter- Downloaded from mines the stability, subcellular localization and eventually The RNase P-mediated endonucleolytic cleavage the functionality of the mature RNA (3,4). Recent studies plays a crucial role in the 3 end processing and cellu- have reported the existence of non-canonical 3 end pro- lar accumulation of MALAT1, a nuclear-retained long cessing mechanisms at several lncRNA loci that generate noncoding RNA that promotes malignancy. The regu- non-polyadenylated RNAs (5–7). Among them, metastasis- http://nar.oxfordjournals.org/ lation of this cleavage event is largely undetermined. associated lung adenocarcinoma transcript 1 (MALAT1; Here we characterize a broadly expressed natural an- also known as NEAT2) and multiple endocrine neoplasia- tisense transcript at the MALAT1 locus, designated ␤ (MEN␤; also known as NEAT1) RNAs are unique as as TALAM1, that positively regulates MALAT1 levels they are highly abundant linear transcripts.
    [Show full text]
  • Expression of Metastasis‑Associated Lung Adenocarcinoma Transcript 1 Long Non‑Coding RNA in Vitro and in Patients with Non‑Small Cell Lung Cancer
    ONCOLOGY LETTERS 15: 9443-9449, 2018 Expression of metastasis‑associated lung adenocarcinoma transcript 1 long non‑coding RNA in vitro and in patients with non‑small cell lung cancer LING LIN1, HAIYAN LI1, YEFEI ZHU1, SUSU HE1 and HONGFEI GE2 Departments of 1Respiratory Medicine and 2Cardiothoracic Surgery, Taizhou Hospital of Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China Received August 1, 2017; Accepted January 16, 2018 DOI: 10.3892/ol.2018.8531 Abstract. The present study aimed to investigate the asso- significantly increased in NSCLC tissues and was revealed to ciation between the expression of metastasis-associated lung serve a role in the progression of NSCLC. adenocarcinoma transcript 1 (MALAT1) long non-coding RNA (lncRNA) and the recurrence of non-small cell lung Introduction cancer (NSCLC) and to elucidate the potential mecha- nisms of MALAT1 in vitro. Between 1 June 1, 2010 and Lung cancer is the most common type of cancer world- December 30, 2016, NSCLC tumor tissues and adjacent wide (1), and 85% of lung cancer cases are diagnosed as non-cancerous tissues were obtained from 120 patients with non-small cell lung cancer (NSCLC) (2). In China alone, NSCLC, who had undergone surgical resection at Taizhou ~7,333,000 patients were diagnosed with NSCLC and, of these, Hospital of Wenzhou Medical University (Linhai, China). The ~6,102,000 patients succumbed to mortality in 2015 (3). With total RNA of tissues and cells were extracted and the expres- increased levels of environmental pollution, the incidence of sion of MALAT1 was determined using a wound healing NSCLC and the mortality rate of patients with this disease assay and reverse transcription quantitative polymerase chain have increased significantly (1), resulting in increased health reaction.
    [Show full text]
  • Clinical Significance of Long Non-Coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer
    Available online at www.annclinlabsci.org 418 Annals of Clinical & Laboratory Science, vol. 46, no. 4, 2016 Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer Yufeng Miao1,2,*, Rengen Fan3,*, Lige Chen4, and Haixin Qian1 1Department of General Surgery, The First Affiliated Hospital of Soochow University, 2Department of Medical Oncol- ogy, Yancheng City No.1 People's Hospital, Yancheng, 3Department of General Surgery, Yancheng City No.1 People's Hospital, Yancheng, and 4Department of Pharmacy, Yancheng City No.1 People's Hospital, Yancheng, China Abstract. Long non-coding RNAs (lncRNAs) have been proven to serve a critical role in cancer develop- ment and progression. The aim of this study was to elucidate clinical significance of lncRNA MALAT1 expression in breast cancer (BC). A total of 78 BC patients treated with radical resection were enrolled in this study. Quantitative reverse transcription-polymerase chain reaction was used to detect MALAT1 ex- pression in tissues and serum samples. The receiver operating characteristics (ROC) curve was constructed to describe diagnostic specificity and sensitivity. Lentivirus-mediated RNA interference was used to knock- down MALAT1 in the MDA-MB-231 cell line, and then cell proliferation and invasion were explored. Results showed that MALAT1 expression was significantly up-regulated in 85.9% (67/78) of cancerous tissues compared with normal counterparts (P<0.01). Further, an elevated MALAT1 expression in BC tis- sue was significantly associated with lymph metastasis (P=0.037) and adverse 5-year disease-free survival (mean 48.5 months vs 62.7 months, P=0.012).
    [Show full text]
  • Structural Insights Into the RNA Methyltransferase Domain Of
    www.nature.com/scientificreports OPEN Structural insights into the RNA methyltransferase domain of METTL16 Received: 12 December 2017 Agnieszka Ruszkowska1, Milosz Ruszkowski2, Zbigniew Dauter2 & Jessica A. Brown1 Accepted: 16 March 2018 N6-methyladenosine (m6A) is an abundant modifcation in messenger RNA and noncoding RNAs that Published: xx xx xxxx afects RNA metabolism. Methyltransferase-like protein 16 (METTL16) is a recently confrmed m6A RNA methyltransferase that methylates U6 spliceosomal RNA and interacts with the 3′-terminal RNA triple helix of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1). Here, we present two X-ray crystal structures of the N-terminal methyltransferase domain (residues 1–291) of human METTL16 (METTL16_291): an apo structure at 1.9 Å resolution and a post-catalytic S-adenosylhomocysteine- bound complex at 2.1 Å resolution. The structures revealed a highly conserved Rossmann fold that is characteristic of Class I S-adenosylmethionine-dependent methyltransferases and a large, positively charged groove. This groove likely represents the RNA-binding site and it includes structural elements unique to METTL16. In-depth analysis of the active site led to a model of the methyl transfer reaction catalyzed by METTL16. In contrast to the major m6A methyltransferase heterodimer METTL3/ METTL14, full-length METTL16 forms a homodimer and METTL16_291 exists as a monomer based on size-exclusion chromatography. A native gel-shift assay shows that METTL16 binds to the MALAT1 RNA triple helix, but monomeric METTL16_291 does not. Our results provide insights into the molecular structure of METTL16, which is distinct from METTL3/METTL14. N6-methyladenosine (m6A) is the product of a dynamic and abundant modifcation in eukaryotic messenger RNA (mRNA) and noncoding RNAs (ncRNA)1 that afects RNA stability2, pre-mRNA processing3, microRNA biogen- esis4 and translation efciency5.
    [Show full text]
  • Long Non-Coding RNA MALAT1 Gene Polymorphism Is Associated with Disease-Free Survival in Bladder Cancer Patients
    Galician medical journal 2020 Vol. 27, Issue 2, E202025 DOI: 10.21802/gmj.2020.2.5 Research Article Long Non-Coding RNA MALAT1 Gene Polymorphism is Associated with Disease-Free Survival in Bladder Cancer Patients Andrii Volkogon*, Olena Kolnoguz, Viktoriia Harbuzova, Alexander Ataman Abstract The objective of the research was to study the possible association between MALAT1 gene rs3200401 poly- morphism and the survival of patients with bladder cancer and clinicopathological characteristics in bladder cancer. Materials and Methods. The venous blood of 141 patients with transitional cell carcinoma of the urinary bladder was used for study. Genotyping of MALAT1 gene rs3200401 polymorphism was performed by real-time polymerase chain reaction using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) and Taq-Man Assays (TaqMan©SNP Assay C 3246069 10). Statistical analysis was performed using the SPSS software package (version 17.0). The Kaplan-Meier estimator and Cox regression were used to check the possible association between MALAT1 rs3200401-genotypes and the age of transitional cell carcinoma of the urinary bladder onset. P values < 0.05 were considered as statistically significant. Results. The obtained results revealed that hemoglobin concentration was lower in patients with transitional cell carcinoma of the urinary bladder and rs3200401TT-genotype than in patients with rs3200401CC-genotype (p = 0.024). Herewith, fasting glucose, creatinine concentration, and tumor width were significantly higher in patients with
    [Show full text]
  • Downregulation of Long Non-Coding RNA MALAT1 Induces Tumor Progression of Human Breast Cancer Through Regulating CCND1 Expression
    Open Life Sci. 2016; 11: 232–236 Topical Issue on Cancer Signaling, Metastasis and Targeted Therapy Open Access Research Article Zhang Yang, Wang Lu, Li Ning, Dai Hao, Sun Jian, Cai Hai-Feng* Downregulation of long non-coding RNA MALAT1 induces tumor progression of human breast cancer through regulating CCND1 expression DOI 10.1515/biol-2016-0032 Received July 1, 2016; accepted August 16, 2016 1 Introduction Abstract: Objective: Metastasis-associated lung Breast cancer is the most common malignancy among adenocarcinoma transcript 1 (MALAT1) is already known females, and is also the second leading cause of cancer- to be involved in the development and progression of related mortality in the world [1,2]. During the past few many types of tumors. In the present study, we set to years advances have been made in its treatment. However, seek the role of MALAT1and the molecular mechanisms the incidences of breast cancer are on the rise recently [3]. in breast cancer. Methods: MALAT1 mRNA expression The prognosis of patients with breast cancer is still poor, level was measured by real-time PCR in selected tissues particularly due to the frequent vital organ metastasis and breast cancer cell lines. SiRNAs targeting MALAT1 [4-6]. Once metastasis occurs, the 5-year survival rate is were employed to knockdown the endogenous MALAT1. less than 25% [7]. Therefore, it is urgent to identify novel Then cell counting method and colony formation biomarkers to serve as possible therapeutic targets for method were applied to reveal the proliferation changes the treatment of breast cancer. In addition, a deeper after MALAT1 was suppressed.
    [Show full text]
  • Curcumin Combining with Si-MALAT1 Inhibits the Invasion and Migration of Colon Cancer SW480 Cells
    Brazilian Journal of Pharmaceutical Sciences Original Article http://dx.doi.org/10.1590/s2175-97902019000118276 Curcumin combining with si-MALAT1 inhibits the invasion and migration of colon cancer SW480 cells Dai Wei1, LI Shi Yun1Δ, Xiao Dejun1, Liu Cong1, Jin-Hua He2, Lin Yan*,1 1Department of Clinical Laboratory, Gangzhou People’s Hospital, Ganzhou, China, 2Department of Laboratory Medicine, Central Hospital of Panyu District, Guangzhou, Guangdong, China To study the effect of small interfering RNA targeting metastasis-associated lung adenocarcinoma transcript1 (si-MALAT1) combining with curcumin on the invasion and migration abilities of human colon cancer SW480 cells, and to explore the involved molecular mechanism. The recombinant lentiviral vector expressing si-MALAT1 was constructed, and its titer was determined by gradient dilution method. The colon cancer SW480 cells with stable expression of si-MALAT1 was established, followed by treatment with curcumin at different concentrations. The effect of curcumin or si-MALAT1 alone and the combination of the two on the cell activity was detected by MTT assay. The cell invasion and migration abilities were detected by transwell and scratch-wound assay. The relative expression level of MALAT1 was detected by RT-qPCR. The protein expression was determined by Western blot analysis. The IC50 of curcumin alone was 77.69 µmol/L, which was 51.17 mol/L when combined with curcumin and random sequence. The IC50 of curcumin was 30.02 µmol/L when combined with si-MALAT1. The increased susceptibility multiples was 2.58. The wound healing rates were 30.9% and 67.5% after treatment with si-MALAT1 combined with curcumin for 24 hrs and 48 hrs, respectively.
    [Show full text]
  • MALAT1 Long Ncrna Promotes Gastric Cancer Metastasis by Suppressing PCDH10
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 11 MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10 Ying Qi1, Hong Sain Ooi2, Jun Wu3, Jian Chen1, Xiaoli Zhang1, Sheng Tan4, Qing Yu4, Yuan-Yuan Li5,6, Yani Kang1, Hua Li1, Zirui Xiong4, Tao Zhu4, Bingya Liu1,7, Zhifeng Shao1, Xiaodong Zhao1 1 School of Biomedical Engineering, Bio-ID Research Center, State Key Laboratory for Oncogenes and Related Genes, Shanghai Jiao Tong University, Shanghai, China 2 Department of Biomedicine, Aarhus University, Aarhus, Denmark 3Department of Automation, Shanghai Jiao Tong University, Shanghai, China 4Laboratory of Molecular Tumor Pathology, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China 5 Shanghai Center for Bioinformatics Technology, Shanghai, China 6Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai, China 7 Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence to: Bingya Liu, e-mail: [email protected] Xiaodong Zhao, e-mail: [email protected] Keywords: EZH2, RIP-seq, MALAT1, gastric cancer, transcriptional silencing Received: September 29, 2015 Accepted: January 23, 2016 Published: February 09, 2016 ABSTRACT EZH2, the catalytic component of polycomb repressive complex 2 (PRC2), is frequently overexpressed in human cancers and contributes to tumor initiation and progression, in part through transcriptional silencing of tumor suppressor genes. A number of noncoding RNAs (ncRNAs) recruit EZH2 to specific chromatin loci, where they modulate gene expression. Here, we used RNA immunoprecipitation sequencing (RIP-seq) to profile EZH2-associated transcripts in human gastric cancer cell lines. We identified 8,256 transcripts, including both noncoding and coding transcripts, some of which were derived from cancer-related loci.
    [Show full text]